Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis
Clicks: 13
ID: 324556
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
3.6
/100
13 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #13 of 47 articles by views in Rheumatology Advances in Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract is not available for this article.
Login to Search Abstract
| Reference Key |
openalex_W7202119690
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | I. Monjo, Marta Novella-Navarro, Marina Molinari-Pérez, M. Sanz-Jardón, Gema Bonilla, María Ángeles González-Fernández, Eugenio de Miguel, Chamaida Plasencia‐Rodríguez |
| Journal | Rheumatology Advances in Practice |
| Year | 2026 |
| DOI |
10.1093/rap/rkag089
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.